EHA 2025: CEO Jonathan Dickinson discusses Innate Pharma's NK cell engager platform (ANKET), recent ASCO data for Lacutamab, and other program updates
He describes Innate's NK cell platform and covers programs targeting CD20, CD123, BCMA, and B7-H3. Plus Lacutamab data, updates on the company's Nectin-4 ADC, and Monalizumab.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.